Cargando…

Use of oral hydromorphone in a patient with stage D heart failure

Patients with advanced heart failure often experience dyspnea, fatigue, edema, and appetite loss. If these symptoms are refractory to treatment, palliative care via a team approach is necessary. We describe a patient with stage D heart failure whose dyspnea and overall condition improved with compre...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Tomohiro, Nakamura, Mari, Shibasaki, Yumiko, Mizukami, Sachie, Tomita, Haruki, Hirai, Masaru, Matsumoto, Mitsunari, Ishida, Takeshi, Momomura, Shin-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326605/
https://www.ncbi.nlm.nih.gov/pubmed/34377492
http://dx.doi.org/10.1177/2050313X211037445
_version_ 1783731862653370368
author Nakamura, Tomohiro
Nakamura, Mari
Shibasaki, Yumiko
Mizukami, Sachie
Tomita, Haruki
Hirai, Masaru
Matsumoto, Mitsunari
Ishida, Takeshi
Momomura, Shin-ichi
author_facet Nakamura, Tomohiro
Nakamura, Mari
Shibasaki, Yumiko
Mizukami, Sachie
Tomita, Haruki
Hirai, Masaru
Matsumoto, Mitsunari
Ishida, Takeshi
Momomura, Shin-ichi
author_sort Nakamura, Tomohiro
collection PubMed
description Patients with advanced heart failure often experience dyspnea, fatigue, edema, and appetite loss. If these symptoms are refractory to treatment, palliative care via a team approach is necessary. We describe a patient with stage D heart failure whose dyspnea and overall condition improved with comprehensive medical treatments including conventional medications for heart failure, continuous infusions of catecholamine and diuretic, and oral hydromorphone. A 67-year-old man with a 12-year history of dilated cardiomyopathy was admitted to our hospital due to exacerbation of heart failure. Despite continuous infusion of catecholamine and diuretic, his dyspnea and liver and renal function continued to worsen. Oral hydromorphone was administered to relieve his refractory dyspnea, which also improved his conditions, continuous infusion of the catecholamine and diuretic could withdraw. Oral low-dose hydromorphone used in the present case might be a helpful agent for treating dyspnea in stage D heart failure patients with renal dysfunction.
format Online
Article
Text
id pubmed-8326605
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-83266052021-08-09 Use of oral hydromorphone in a patient with stage D heart failure Nakamura, Tomohiro Nakamura, Mari Shibasaki, Yumiko Mizukami, Sachie Tomita, Haruki Hirai, Masaru Matsumoto, Mitsunari Ishida, Takeshi Momomura, Shin-ichi SAGE Open Med Case Rep Case Report Patients with advanced heart failure often experience dyspnea, fatigue, edema, and appetite loss. If these symptoms are refractory to treatment, palliative care via a team approach is necessary. We describe a patient with stage D heart failure whose dyspnea and overall condition improved with comprehensive medical treatments including conventional medications for heart failure, continuous infusions of catecholamine and diuretic, and oral hydromorphone. A 67-year-old man with a 12-year history of dilated cardiomyopathy was admitted to our hospital due to exacerbation of heart failure. Despite continuous infusion of catecholamine and diuretic, his dyspnea and liver and renal function continued to worsen. Oral hydromorphone was administered to relieve his refractory dyspnea, which also improved his conditions, continuous infusion of the catecholamine and diuretic could withdraw. Oral low-dose hydromorphone used in the present case might be a helpful agent for treating dyspnea in stage D heart failure patients with renal dysfunction. SAGE Publications 2021-07-31 /pmc/articles/PMC8326605/ /pubmed/34377492 http://dx.doi.org/10.1177/2050313X211037445 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Nakamura, Tomohiro
Nakamura, Mari
Shibasaki, Yumiko
Mizukami, Sachie
Tomita, Haruki
Hirai, Masaru
Matsumoto, Mitsunari
Ishida, Takeshi
Momomura, Shin-ichi
Use of oral hydromorphone in a patient with stage D heart failure
title Use of oral hydromorphone in a patient with stage D heart failure
title_full Use of oral hydromorphone in a patient with stage D heart failure
title_fullStr Use of oral hydromorphone in a patient with stage D heart failure
title_full_unstemmed Use of oral hydromorphone in a patient with stage D heart failure
title_short Use of oral hydromorphone in a patient with stage D heart failure
title_sort use of oral hydromorphone in a patient with stage d heart failure
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326605/
https://www.ncbi.nlm.nih.gov/pubmed/34377492
http://dx.doi.org/10.1177/2050313X211037445
work_keys_str_mv AT nakamuratomohiro useoforalhydromorphoneinapatientwithstagedheartfailure
AT nakamuramari useoforalhydromorphoneinapatientwithstagedheartfailure
AT shibasakiyumiko useoforalhydromorphoneinapatientwithstagedheartfailure
AT mizukamisachie useoforalhydromorphoneinapatientwithstagedheartfailure
AT tomitaharuki useoforalhydromorphoneinapatientwithstagedheartfailure
AT hiraimasaru useoforalhydromorphoneinapatientwithstagedheartfailure
AT matsumotomitsunari useoforalhydromorphoneinapatientwithstagedheartfailure
AT ishidatakeshi useoforalhydromorphoneinapatientwithstagedheartfailure
AT momomurashinichi useoforalhydromorphoneinapatientwithstagedheartfailure